Cytokinetics, Incorporated (NASDAQ: CYTK)

Cytokinetics, Incorporated (NASDAQ: CYTK), a biopharmaceutical company, is devoted to the discovery, development and commercialization of innovative small molecule drugs. The company’s cardiovascular disease program is focused on cardiac myosin, which is a motor protein vital to cardiac muscle contraction. CK-1827452, Cytokinetics’ lead compound from this program, is a small molecule cardiac myosin activator that has entered Phase II clinical trials for the treatment of heart failure. For further information, visit the Company’s web site at www.cytokinetics.com.